公开(公告)号：US20200085874A1

公开(公告)日：2020-03-19

申请号：US16692108

申请日：2019-11-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K16/24 ,  A61K39/12 ,  C07K14/47 ,  A61K39/00 ,  C07K14/54 ,  C07K7/06 ,  A61P35/02 ,  A61K38/08 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/39 ,  C12N5/0783 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200055899A1

公开(公告)日：2020-02-20

申请号：US16671994

申请日：2019-11-01

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K35/17 ,  C07K7/06 ,  C07K14/725 ,  C07K14/47 ,  A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  G01N33/68

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200054727A1

公开(公告)日：2020-02-20

申请号：US16669622

申请日：2019-10-31

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/74 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/725 ,  C07K14/47 ,  C07K7/08 ,  C07K7/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200031899A1

公开(公告)日：2020-01-30

申请号：US16590933

申请日：2019-10-02

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  G01N33/569 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/725 ,  C12Q1/6886 ,  C07K14/47 ,  C07K16/30 ,  A61K38/08 ,  C07K7/02 ,  C07K7/06 ,  G01N33/566 ,  C07K16/18 ,  C12N5/0783 ,  C12N9/64 ,  C07K14/00 ,  A61K38/17 ,  G01N33/50 ,  A61K38/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200024325A1

公开(公告)日：2020-01-23

申请号：US16591083

申请日：2019-10-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  G01N33/569 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/725 ,  C12Q1/6886 ,  C07K14/47 ,  C07K16/30 ,  A61K38/08 ,  C07K7/02 ,  C07K7/06 ,  G01N33/566 ,  C07K16/18 ,  C12N5/0783 ,  C12N9/64 ,  C07K14/00 ,  A61K38/17 ,  G01N33/50 ,  A61K38/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200009237A1

公开(公告)日：2020-01-09

申请号：US16582096

申请日：2019-09-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/00 ,  C12N15/115 ,  C07K14/47 ,  C07K7/06 ,  A61K38/08 ,  C07K14/72 ,  A61P35/00 ,  A61P35/02 ,  A61K38/17 ,  A61K35/17 ,  C07K14/725

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200000902A1

公开(公告)日：2020-01-02

申请号：US16554139

申请日：2019-08-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190374626A1

公开(公告)日：2019-12-12

申请号：US16552873

申请日：2019-08-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  C12N5/0783 ,  G01N33/574 ,  G01N33/68 ,  C07K16/30 ,  C07K14/47 ,  C12N15/115 ,  C12Q1/6886 ,  C07K14/725

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190315832A1

公开(公告)日：2019-10-17

申请号：US16413192

申请日：2019-05-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  G01N33/574 ,  C07K14/635 ,  C07K14/47 ,  C07K16/28 ,  C07K14/725 ,  C12N5/0783 ,  A61K39/00 ,  C12Q1/6886

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190241630A1

公开(公告)日：2019-08-08

申请号：US16388915

申请日：2019-04-19

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K14/725 ,  A61P35/00 ,  C12N5/0783 ,  C07K16/30 ,  C12N15/10 ,  G01N33/574 ,  A61K39/00 ,  C12N15/115 ,  C07K14/74

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K39/001102 ,  A61K2039/5158 ,  A61K2039/572 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2818 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0638 ,  C12N15/1062 ,  C12N15/115 ,  C12N2501/50 ,  G01N33/57492

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.